Drug research: marketing before evidence, sales before safety.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Commentary: Reconsidering Pharmaceutical Research and Development Investments.Healthcare policy = Politiques de sante · 2023
   Article
2. Reconsidering evidence-based management of endometriosis.Facts, views & vision in ObGyn · 2022
   Article
3. Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.Journal of addiction research & therapy · 2012
   Article
4. [From the design of use study to the assessment of the benefit: with or without pharmaceutical industry?].Medizinische Klinik (Munich, Germany : 1983) · 2010
   Article

Corrections and comments

• Comment on
  The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as